Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis

NeuroImmunoModulation

Volumn 22, Issue 3, 2014, Pages 203-212

  Abad, Catalina ^a   Cheung Lau, Gardenia ^a   Coûté Monvoisin, Anne Claire ^a   Waschek, James A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; Inflammation; Knockout mice; Neuropeptide; Trinitrobenzene sulfonic acid; Vasoactive intestinal peptide

Indexed keywords

INTERLEUKIN 6; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; CYTOKINE; MESSENGER RNA; PEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; FEMALE; GENE DELETION; HISTOPATHOLOGY; IMMUNOSTIMULATION; IN VITRO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN CELL; WEIGHT REDUCTION; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COLON; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; T LYMPHOCYTE; TIME FACTOR;

ANIMALS; CELL PROLIFERATION; COLITIS; COLON; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEROXIDASE; RNA, MESSENGER; T-LYMPHOCYTES; TIME FACTORS; TRINITROBENZENESULFONIC ACID; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84921325523     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000364912     Document Type: Article

References (45)

1. Baumgart DC, Sandborn WJ: Crohn's disease. Lancet 2013; 380: 1590-1605.
2. Monteleone I, Pallone F, Monteleone G: Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med 2011; 9: 122.
3. Strober W, Fuss IJ: Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
4. Ahluwalia JP: Immunotherapy in inflammatory bowel disease. Med Clin North Am 2012; 96: 525-544, x.
5. Ngo B, Farrell CP, Barr M, Wolov K, Bailey R, Mullin JM, Thornton JJ: Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety. Curr Mol Pharmacol 2010; 3: 145-152.
6. Margolis KG, Gershon MD: Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol 2009; 25: 503-511.
7. Said SI, Mutt V: Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169: 1217-1218.
8. Lakhan SE, Kirchgessner A: Neuroinflammation in inflammatory bowel disease. J Neuroinflammation 2010; 7: 37.
9. Fahrenkrug J: Vasoactive intestinal peptide; in Pollock DM (ed) : Comprehensive Physiology. New York, John Wiley & Sons, 2011, pp 611-629.
10. Moody TW, Chan D, Fahrenkrug J, Jensen RT: Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 2003; 9: 495-509.
11. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI: Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012; 166: 4-17.
12. Delgado M, Pozo D, Ganea D: The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56: 249-290.
13. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003; 124: 961-971.
14. Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, Garcia-Gomez M, Leceta J, Gomariz RP: cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis 2005; 11: 674-684.
15. Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, Gomariz RP, Martinez C: Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann NY Acad Sci 2006; 1070: 129-134.
16. Gomariz RP, Arranz A, Abad C, Torroba M, Martinez C, Rosignoli F, Garcia-Gomez M, Leceta J, Juarranz Y: Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol 2005; 78: 491-502.
17. Conlin VS, Wu X, Nguyen C, Dai C, Vallance BA, Buchan AM, Boyer L, Jacobson K: Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with citrobacter rodentium-induced colitis. Am J Physiol Gastrointest Liver Physiol 2009; 297:G735-G750.
18. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V, Hu Z, Liu X, Waschek JA: Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 2003; 285:R939-R949.
19. Gay J, Kokkotou E, O'Brien M, Pothoulakis C, Karalis KP: Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acidinduced colitis in mice. Putative effect of antiinflammatory cytokines. Neuroimmunomodulation 2006; 13: 114-121.
20. Delgado M: VIP: a very important peptide in T helper differentiation. Trends Immunol 2003; 24: 221-224.
21. van Lierop PP, de Haar C, Lindenbergh-Kortleve DJ, Simons-Oosterhuis Y, van Rijt LS, Lambrecht BN, Escher JC, Samsom JN, Nieuwenhuis EE: T-cell regulation of neutrophil infiltrate at the early stages of a murine colitis model. Inflamm Bowel Dis 2010; 16: 442-451.
22. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J: Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 1999; 93: 126-138.
23. Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D, Gomariz RP: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL- 6. J Immunol 1999; 162: 1200-1205.
24. Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J: Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 2002; 80: 16-24.
25. Duffy LC, Zielezny MA, Riepenhoff-Talty M, Byers TE, Marshall J, Weiser MM, Graham S, Ogra PL: Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1528-1535.
26. O'Morain C, Bishop AE, McGregor GP, Levi AJ, Bloom SR, Polak JM, Peters TJ: Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. Gut 1984; 25: 57-61.
27. Schneider J, Jehle EC, Starlinger MJ, Neunlist M, Michel K, Hoppe S, Schemann M: Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn's disease. Neurogastroenterol Motil 2001; 13: 255-264.
28. Bishop AE, Polak JM, Bryant MG, Bloom SR, Hamilton S: Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease. Gastroenterology 1980; 79: 853-860.
29. Kubota Y, Petras RE, Ottaway CA, Tubbs RR, Farmer RG, Fiocchi C: Colonic vasoactive intestinal peptide nerves in inflammatory bowel disease. Gastroenterology 1992; 102: 1242-1251.
30. Baticic L, Detel D, Kucic N, Buljevic S, Pugel EP, Varljen J: Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. J Cell Biochem 2011; 112: 3322-3333.
31. Sigalet DL, Wallace L, De Heuval E, Sharkey KA: The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation. Neurogastroenterol Motil 2010; 22:e1318-e1350.
32. Linden DR, Couvrette JM, Ciolino A, Mc-Quoid C, Blaszyk H, Sharkey KA, Mawe GM: Indiscriminate loss of myenteric neurones in the TNBS-inflamed guinea-pig distal colon. Neurogastroenterol Motil 2005; 17: 751-760.
33. Abad C, Tan YV, Lopez R, Nobuta H, Dong H, Phan P, Feng JM, Campagnoni AT, Waschek JA: Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010; 107: 19555-19560.
34. Abad C, Tan YV, Cheung-Lau G, Nobuta H, Waschek JA: VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLoS One 2012; 7: e36922.
35. Yusta B, Holland D, Waschek JA, Drucker DJ: Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice. Endocrinology 2012; 153: 2623-2632.
36. Lelievre V, Favrais G, Abad C, Adle-Biassette H, Lu Y, Germano PM, Cheung-Lau G, Pisegna JR, Gressens P, Lawson G, Waschek JA: Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides 2007; 28: 1688-1699.
37. Pfeiffer CJ, Qiu B, Lam SK: Reduction of colonic mucus by repeated short-term stress enhances experimental colitis in rats. J Physiol Paris 2001; 95: 81-87.
38. Krimi RB, Kotelevets L, Dubuquoy L, Plaisancie P, Walker F, Lehy T, Desreumaux P, Van Seuningen I, Chastre E, Forgue-Lafitte ME, Marie JC: Resistin-like molecule beta regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. Inflamm Bowel Dis 2008; 14: 931-941.
39. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Buller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AW: Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-129.
40. Manichanh C, Borruel N, Casellas F, Guarner F: The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 599-608.
41. Yadav M, Huang MC, Goetzl EJ: VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Cell Immunol 2011; 267: 124-132.
42. Delgado M, Munoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor- κB and cAMP response element-binding protein/c-Jun. J Biol Chem 1998; 273: 31427-31436.
43. Delgado M, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP- 1. J Biol Chem 2001; 276: 369-380.
44. Delgado M, Martinez C, Johnson MC, Gomariz RP, Ganea D: Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 1996; 68: 27-38.
45. Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B: Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 2001; 166: 2522-2530.